Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05748873 · ClinicalTrials.gov registry record · Phase 1
Promising ROd-cone DYstrophy Gene therapY
A Phase 1 study of Retinitis Pigmentosa, sponsored by SparingVision.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT05748873 is a Phase 1 study of Retinitis Pigmentosa that is actively recruiting participants, run by SparingVision. The registered enrollment target is 33 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05748873, a Phase 1 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by SparingVision.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Conditions Studied
Interventions
- DRUG SPVN06
Study Locations (6)
Florida
- Bascom Palmer Eye Institute/University of Miami - Miami
Massachusetts
- Mass Eye and Ear - Boston
Oregon
- Casey Eye Institute - Portland
Pennsylvania
- UPMC Eye Center - Pittsburgh
Texas
- Retina Foundation of the Southwest - Dallas
Other
- CHNO XV-XX Paris - CIC 1423 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2030-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05748873
The ClinicalTrials.gov registry entry for NCT05748873 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The listed sponsor is SparingVision, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which SPVN06 is the first listed.
NCT05748873 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Massachusetts, Oregon.
Frequently Asked Questions
What is clinical trial NCT05748873 about?
NCT05748873 is a clinical study titled "Promising ROd-cone DYstrophy Gene therapY". This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
What is the current status of trial NCT05748873?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-04-12. Estimated completion is 2030-09.
What conditions does trial NCT05748873 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT05748873?
The interventions under investigation include: SPVN06 (DRUG).
Who is sponsoring clinical trial NCT05748873?
This trial is sponsored by SparingVision, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05748873 being conducted?
This trial has 6 study locations across Florida, Massachusetts, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.